CorMedix Financial Statements From 2010 to 2025

CRMD Stock  USD 10.43  0.04  0.38%   
CorMedix financial statements provide useful quarterly and yearly information to potential CorMedix investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on CorMedix financial statements helps investors assess CorMedix's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting CorMedix's valuation are summarized below:
Gross Profit
10.2 M
Market Capitalization
635.3 M
Enterprise Value Revenue
48.1003
Revenue
12.3 M
Earnings Share
(0.80)
There are over one hundred nineteen available fundamental signals for CorMedix, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of CorMedix's prevailing performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 180.9 M. The current year's Enterprise Value is expected to grow to about 140.3 M

CorMedix Total Revenue

65,408

Check CorMedix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CorMedix's main balance sheet or income statement drivers, such as Interest Expense of 29.3 K, Selling General Administrative of 43.2 M or Research Development of 10.2 M, as well as many indicators such as Price To Sales Ratio of 1.6 K, Dividend Yield of 0.0179 or PTB Ratio of 2.58. CorMedix financial statements analysis is a perfect complement when working with CorMedix Valuation or Volatility modules.
  
Check out the analysis of CorMedix Correlation against competitors.
For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.

CorMedix Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets99.1 M94.4 M36.9 M
Slightly volatile
Other Current Liabilities8.4 MM3.4 M
Slightly volatile
Total Current Liabilities10.8 M10.3 M5.9 M
Slightly volatile
Accounts Payable5.2 M4.9 M2.1 M
Slightly volatile
Cash52.7 M50.2 M22.6 M
Slightly volatile
Other Current Assets1.6 M1.5 M808.4 K
Slightly volatile
Total Liabilities7.3 M13.7 M6.8 M
Slightly volatile
Common Stock36.3 K63.2 K38.4 K
Slightly volatile
Property Plant Equipment2.9 M2.7 M856.4 K
Slightly volatile
Short and Long Term Debt Total570.8 K600.9 K3.5 M
Slightly volatile
Property Plant And Equipment NetM2.9 M937.5 K
Slightly volatile
Non Current Assets Total3.2 MMM
Slightly volatile
Cash And Short Term Investments91.8 M87.4 M34.5 M
Slightly volatile
Common Stock Total Equity36.2 K43.8 K35.8 K
Slightly volatile
Common Stock Shares Outstanding61.5 M58.5 M22.3 M
Slightly volatile
Property Plant And Equipment Gross3.7 M3.5 M1.1 M
Slightly volatile
Total Current Assets95.9 M91.4 M35.9 M
Slightly volatile
Short Term Debt128.8 K135.6 K955.8 K
Slightly volatile
Other Liabilities31.5 K33.2 K357.7 K
Pretty Stable
Capital Surpluse372.3 M354.6 M187.9 M
Slightly volatile
Current Deferred Revenue1.9 KK24.6 K
Pretty Stable
Net Invested Capital43.1 M80.7 M28 M
Slightly volatile
Net Working Capital42.1 M78.3 M27.3 M
Slightly volatile
Long Term Debt Total4.9 M5.5 MM
Slightly volatile
Capital Stock40.7 K49.6 K79.4 K
Slightly volatile
Capital Lease Obligations754.5 K767.8 K311 K
Slightly volatile
Non Current Liabilities Other633.9 K922.8 K307.2 K
Slightly volatile

CorMedix Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative43.2 M41.2 M14.8 M
Slightly volatile
Research Development10.2 M15.1 M10.2 M
Slightly volatile
Depreciation And Amortization79.6 K81.4 K77.1 K
Slightly volatile
Other Operating Expenses59.1 M56.3 M25.4 M
Slightly volatile
Total Operating Expenses59.1 M56.3 M25.2 M
Slightly volatile
Preferred Stock And Other Adjustments28.3 K29.8 K123.5 K
Slightly volatile
Interest Income3.2 M3.1 M649.8 K
Slightly volatile
Reconciled Depreciation83.2 K81.4 K59.5 K
Slightly volatile

CorMedix Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Total Cash From Financing Activities67.5 M64.3 M28.5 M
Slightly volatile
End Period Cash Flow52.9 M50.4 M22.6 M
Slightly volatile
Stock Based Compensation6.6 M6.3 M2.8 M
Slightly volatile
Begin Period Cash Flow52.4 M49.9 M20.3 M
Slightly volatile
Depreciation46.3 K81.4 K46.7 K
Slightly volatile
Other Non Cash Items115.3 K121.3 K1.9 M
Pretty Stable
Change To Netincome3.4 M4.8 M3.1 M
Pretty Stable
Issuance Of Capital Stock35.2 M64.2 M29.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.6 KKK
Slightly volatile
Dividend Yield0.01790.02020.022
Slightly volatile
Days Sales Outstanding16299.74190
Slightly volatile
Average Payables1.4 MM1.7 M
Slightly volatile
Stock Based Compensation To Revenue90.2371.55191
Slightly volatile
Capex To Depreciation2.824.163.897
Pretty Stable
EV To Sales1.3 K2.2 K2.5 K
Slightly volatile
Inventory Turnover0.08340.08784.226
Pretty Stable
Days Of Inventory On Hand3.5 K3.4 K1.2 K
Slightly volatile
Payables Turnover0.05250.05520.2378
Slightly volatile
Sales General And Administrative To Revenue20.5321.61455
Slightly volatile
Average Inventory995.2 K947.9 K486.1 K
Slightly volatile
Research And Ddevelopement To Revenue128188218
Slightly volatile
Capex To Revenue3.333.865.8961
Slightly volatile
Cash Per Share2.391.721.6074
Pretty Stable
Days Payables Outstanding6.5 K6.8 K16.4 K
Slightly volatile
Income Quality0.550.750.7324
Slightly volatile
Current Ratio4.066.275.3605
Slightly volatile
Receivables Turnover3.63.79516
Very volatile
Capex Per Share0.00610.00580.0079
Pretty Stable
Average Receivables26.6 K28 K87.6 K
Slightly volatile
Revenue Per Share0.00180.00190.0123
Pretty Stable
Interest Debt Per Share0.01430.01510.5166
Slightly volatile
Debt To Assets0.00890.00940.6054
Slightly volatile
Operating Cycle3.5 K3.4 K1.3 K
Slightly volatile
Days Of Payables Outstanding6.5 K6.8 K16.4 K
Slightly volatile
Ebt Per Ebit1.361.091.2275
Slightly volatile
Quick Ratio4.016.115.2871
Slightly volatile
Net Income Per E B T0.720.880.8345
Very volatile
Cash Ratio2.773.453.5157
Slightly volatile
Days Of Inventory Outstanding3.5 K3.4 K1.2 K
Slightly volatile
Days Of Sales Outstanding16299.74190
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.810.910.9905
Slightly volatile
Fixed Asset Turnover0.030.03151.2897
Pretty Stable
Debt Ratio0.00890.00940.6054
Slightly volatile
Price Sales Ratio1.6 KKK
Slightly volatile
Asset Turnover0.00120.00120.0078
Pretty Stable

CorMedix Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap180.9 M172.3 M107 M
Slightly volatile
Enterprise Value140.3 M133.6 M86 M
Slightly volatile

CorMedix Fundamental Market Drivers

Forward Price Earnings21.1416
Cash And Short Term Investments76 M

CorMedix Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About CorMedix Financial Statements

CorMedix stakeholders use historical fundamental indicators, such as CorMedix's revenue or net income, to determine how well the company is positioned to perform in the future. Although CorMedix investors may analyze each financial statement separately, they are all interrelated. For example, changes in CorMedix's assets and liabilities are reflected in the revenues and expenses on CorMedix's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in CorMedix. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred RevenueK1.9 K
Cost Of Revenue236.4 K235.3 K
Stock Based Compensation To Revenue 71.55  90.23 
Sales General And Administrative To Revenue 21.61  20.53 
Research And Ddevelopement To Revenue 187.77  128.18 
Capex To Revenue 3.86  3.33 
Ebit Per Revenue(421.38)(442.45)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether CorMedix is a strong investment it is important to analyze CorMedix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CorMedix's future performance. For an informed investment choice regarding CorMedix Stock, refer to the following important reports:
Check out the analysis of CorMedix Correlation against competitors.
For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CorMedix. If investors know CorMedix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CorMedix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.80)
Revenue Per Share
0.212
Quarterly Revenue Growth
(0.47)
Return On Assets
(0.38)
Return On Equity
(0.65)
The market value of CorMedix is measured differently than its book value, which is the value of CorMedix that is recorded on the company's balance sheet. Investors also form their own opinion of CorMedix's value that differs from its market value or its book value, called intrinsic value, which is CorMedix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CorMedix's market value can be influenced by many factors that don't directly affect CorMedix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CorMedix's value and its price as these two are different measures arrived at by different means. Investors typically determine if CorMedix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CorMedix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.